ClinicalTrials.gg
Active, not recruitingNCT07455097COMBINE-PUpdated Mar 6, 2026

COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)

An observational study in Intermediate-risk Prostate Cancer and High-risk Prostate Cancer, sponsored by Heinrich-Heine University, Duesseldorf. Active, not recruiting at 10 sites in 7 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
45 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf — 5 open to participants now, 6 under way, none of them phase 3. Prostatic Neoplasms · Heinrich-Heine University, Duesseldorf.

Started
2026
with 1 other
Observational
4 of 11
3 open now
Registered
11th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, or all of them as a file.
02

Study summary

This retrospective, multicentre comparative analysis aims to evaluate a new staging method for i) improved detection of intraprostatic index lesions, ii) local T-staging and iii) lymph node (LN) staging in men with clinically significant prostate cancer (csPCa) at intermediate/high risk by combining prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging using different tracers ((18)F) DCFPyL, Gallium-68, Fluor-18) and multiparametric magnetic resonance imaging (MRI) in patients with prostate cancer (PCa) who subsequently underwent radical prostatectomy (RP). Another secondary endpoint will be the additional value of PSMA-PET/CT in men with unremarkable MRI. Men at intermediate risk (PSA > 10 ng/ml to 20 ng/ml or Gleason score 7 or cT category 2b) or high risk (PSA > 20 ng/ml or Gleason score ≥ 8 or cT category 2c) who underwent PSMA-PET/CT and mpMRI followed by RP will be analysed in three different subgroups corresponding to the modalities i) PSMA-PET/CT with 18-F-DCFPyL (subgroup/arm A), ii) Gallium-68 PSMA-PET/CT (subgroup/arm B) and Fluorine-18 PSMA-PET/CT (subgroup/arm C).

The validation of the accuracy of the detection of intraprostatic index lesions, local and lymph node staging by MRI and PSMA-PET-CT with different tracers is carried out using the histological radical prostatectomy specimens.

In addition, the prediction of the International Society of Urolgenital Pathology (ISUP) graduation group (GG) within intraprostatic index lesions will be determined using the SUV (standardised uptake value) in PSMA-PET-CT and using ADC values (Apparent Diffusion Coefficient of the diffusion-weighted MRI sequence) in MRI (7,8). The ability of PSMA-PET-CT to predict extraprostatic, i.e. capsule-transcending, tumour growth is also analysed in comparison with MRI. In addition, the correlation of tumour localisation (right vs. left) in relation to positive lymph nodes (right vs. left) is analysed. Finally, the added value of PSMAPET-CT in the case of negative, unsuspicious MRI is determined.

Overall, our analysis aims to improve patient care by analysing the potential of non-invasive "digital biopsy" in terms of lesion detection and prediction of the histological grading group.

In addition, a proof-of-concept for personalised lymph node dissection based on prediction of lymph node metastasis and patient-tailored nerve sparing with accurate prediction of extracapsular extension will be tested based on combined preoperative PSMA-PET and MRI imaging. The results of these two analyses will have a direct impact on clinical practice and the further use of highly specialised imaging.

In addition, this multi-centre data analysis will provide the European Prostate Cancer Center of Excellence (EPCCE) group with a proof-of-concept for future projects.

Read the detailed description

Study protocol - COMBINE-P

  1. Please enter a meaningful study title that describes the project at hand

    COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) - A multicentre retrospective analysis in the European Prostate Cancer Centres of Excellence for Prostate Cancer (EPCCE)

  2. Name and title of the study coordinators, degree/ profession, institute/ clinic

Prof. Dr Jan Philipp Radtke, Deputy Director and Senior Consultant, Department of Urology, Düsseldorf University Hospital Prof. Dr Peter Albers, Clinic Director, Clinic for Urology, Düsseldorf University Hospital Dr Isabelle Busshoff, Assistant Physician, Department of Urology, Düsseldorf University Hospital

2.1 Study Site Coordinators, degree/ profession, institute/ clinic 2.1.1 Germany - University Hospital Munich - Ludwigs-Maximilian-University Munich Prof. Dr Christian Stief, Full Professor of Urology and Chairman, Department of Urology Dr Thilo Westhofen, Consultant, Department of Urology 2.1.2 Germany - University Hospital Tübingen Prof. Dr Arnulf Stenzl, Professor of Urology and Chairman, Department of Urology Prof. Dr Steffen Rausch, Professor of Urology, Department of Urology, University Hospital Tübingen 2.1.3 Germany - University Hospital Bochum Prof. Dr Joachim Nodus, Full Professor of Urology, Marien Hospital Herne University of Ruhr-University Bochum Prof. Dr Florian Roghmann, Professor of Urology, Marien Hospital Herne University of Ruhr-University Bochum 2.1.4 Germany - University Hospital Düsseldorf Prof. Dr Lars Schimmöller, Institute of Diagnostic and Interventional Radiology Prof. Dr Frederik L. Giesel, Department of Nuclear Medicine 2.1.5 United Kingdom - Christie Clinic Foundation Trust Manchaster Prof. Dr Vijay Sangar, Full Professor of Urology, Department of Urology 2.1.6 Belgium - University Hospital Leuven Prof. Dr Steven Joniau, Full Professor of Urology, Department of Urology Prof. Dr Karolien Goffin, Full Professor of Nuclear Medicine , Department of Nuclear Medicine 2.1.7 France - Hospital Civils de Lyon Prof. Dr Alain Ruffion, Full Professor of Urology, Department of Urology 2.1.8 Switzerland - University Hospital Bern Prof. Dr George Thalmann, Professor of Urology, Department of Urology 2.1.9 Italy - Hospital IRCCS San Raffaele Milan Prof. Dr Francesco Montorsi, Full Professor of Urology, Department of Urology Prof. Dr Alberto Briganti, Professor of Urology, Department of Urology Dr Armando Stabile, Consultant, Department of Urology 2.1.10 Austria - University Hospital Vienna Prof. Dr Shahrokh Shariat, Full Professor of Urology, Department of Urology Dr Pawel Rajwa, Consultant, Department of Urology 2.1.11 Sweden - Lund University, Skane University Hospital Prof. Dr Anders Bjartell, Professor of Urology, Department of Urology

3.

a. Is this an initial application or is there already an ethics vote from another EC? First vote

4. Please provide a brief summary of your study. Please explain the aim of the study and what new findings you are expecting

This retrospective, multicentre comparative analysis aims to evaluate a new staging method for i) improved detection of intraprostatic index lesions, ii) local T-staging and iii) lymph node (LN) staging in men with clinically significant prostate cancer (csPCa) at intermediate/high risk by combining prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging using different tracers ((18)F) DCFPyL, Gallium-68, Fluor-18) and multiparametric magnetic resonance imaging (MRI) in patients with prostate cancer (PCa) who subsequently underwent radical prostatectomy (RP). Another secondary endpoint will be the additional value of PSMA-PET/CT in men with unremarkable MRI. Men at intermediate risk (PSA > 10 ng/ml to 20 ng/ml or Gleason score 7 or cT category 2b) or high risk (PSA > 20 ng/ml or Gleason score ≥ 8 or cT category 2c) who underwent PSMA-PET/CT and mpMRI followed by RP will be analysed in three different subgroups corresponding to the modalities i) PSMA-PET/CT with 18-F-DCFPyL (subgroup/arm A), ii) Gallium-68 PSMA-PET/CT (subgroup/arm B) and Fluorine-18 PSMA-PET/CT (subgroup/arm C) (1-6). The validation of the accuracy of the detection of intraprostatic index lesions, local and lymph node staging by MRI and PSMA-PET-CT with different tracers is carried out using the histological radical prostatectomy specimens. In addition, the prediction of the International Society of Urolgenital Pathology (ISUP) graduation group (GG) within intraprostatic index lesions will be determined using the SUV (standardised uptake value) in PSMA-PET-CT and using ADC values (Apparent Diffusion Coefficient of the diffusion-weighted MRI sequence) in MRI (7,8). The ability of PSMA-PET-CT to predict extraprostatic, i.e. capsule-transcending, tumour growth is also analysed in comparison with MRI. In addition, the correlation of tumour localisation (right vs. left) in relation to positive lymph nodes (right vs. left) is analysed. Finally, the added value of PSMAPET- CT in the case of negative, unsuspicious MRI is determined.

Overall, our analysis aims to improve patient care by analysing the potential of non-invasive "digital biopsy" in terms of lesion detection and prediction of the histological grading group.

In addition, a proof-of-concept for personalised lymph node dissection based on prediction of lymph node metastasis and patient-tailored nerve sparing with accurate prediction of extracapsular extension will be tested based on combined preoperative PSMA-PET and MRI imaging. The results of these two analyses will have a direct impact on clinical practice and the further use of highly specialised imaging. In addition, this multi-centre data analysis will provide the European Prostate Cancer Center of Excellence (EPCCE) group with a proof-of-concept for future projects.

5. Please indicate which of the provisions and principles in the applicable version are relevant to the project and will therefore be taken into account and observed during implementation.

a. Professional code of conduct for doctors b. Declaration of Helsinki c. GDPR d. Federal Data Protection Act e. NRW State Data Protection Act f. Health Data Protection Act NRW

6. Please state the exact period to which the planned data collection relates (e.g. "01/2005 - 12/2014" or "01/2007 to the date of application").

Multicentre, retrospective data analysis. At the University Hospital Düsseldorf of the Heinrich-Heine University Düsseldorf, the retrospective data analysis will cover the period 04/2021-04/2023. At the other centres, the retrospective data analysis will cover the period 01/2016-04/2023.

7. Case number planning Please enter the planned number of cases (e.g. n = x patients).

Multicentre n = 600 patients. At the University Hospital Düsseldorf approx. n=60 patients.

8. Informed consent

  1. Was written consent obtained from the patient? No
  2. If "No" In addition to the time and cost involved in following up the treated patients to obtain their "informed consent", the probability of non-consent can be considered lowoverall. The retrospective analysis of the data as part of the research project is based exclusively on data acquired in the course of medically necessary treatment at the Department of Urology. A retrospective collection of additional data is not planned. The data used is extracted from archived data of the Clinic for Urology by employees of the Clinic for Urology who are bound to confidentiality, with immediate anonymisation, so that it is not possible to trace the data back to the individual patient.

The use of the data has no further effect on the treatment of patients. The evaluation does not result in any health or ongoing care risk for the patient. The analysis does not result in any relevant therapy outcomes for the patient. The patients analysed in the retrospective analysis have already consented to the use of their collected data for scientific purposes as part of the MRProRoutine study (study number: 5910R; study registration ID: 201/0341/1).

c. Are there any indications that patients (including individual patients) have objected to their data being used for research purposes? There is no evidence for this exception.

9. Data management

  1. What is the source of the data? Data is collected from archived patient files of patients from the Department of Urology at the University Hospital Düsseldorf. As part of the multicentre, retrospective data analysis, the anonymised data of the HHU patients are compared with those of the Inselspital Bern, the University Hospital Vienna, the Hospital IRCCS San Raffaele Milan, Anser/ERASMUS University Hospital Rotterdam, the Hospital Civils Lyon, University Hospital Leuven/Belgium, University Hospital Lund/Sweden, University Hospital Tübingen, University Hospital Ludwigs- Maximilian University Munich, from the Medico patient information system are stored in a database. In addition, data from the PACS image processing and information systems of the University Hospital Düsseldorf, the Inselspital Bern, the University Hospital Vienna, the Hospital IRCCS San Raffaele Milan, Anser/ERASMUS University Hospital Rotterdam, the Hospital Civils Lyon, the University Hospital Leuven, the University Hospital Lund/Sweden, the University Hospital Tübingen, the Hospital Herne of the University Hospital of the Ludwig Maximilian University Munich are stored retrospectively and anonymised.
  2. For data from patient files: Were the patients treated in your clinic? Yes.
  3. How is the data collected? Anonymised at source.
  4. How is the data coded? By means of an ascending series of numbers.
  5. Who collects the data? Dr Isabelle Bußhoff, Assistant Physician (Clinic for Urology, UKD) Prof Dr Jan Philipp Radtke (Clinic for Urology, UKD) Prof Roghmann Florian (Department of Urology, Marien Hospital Herne) Prof Dr Georg Thalmann (Department of Urology, Inselspital Bern) Prof Dr Shahrokh Shariat (Department of Urology, University Hospital Vienna) Prof Dr Francesco Montorsi (Department of Urology, Hospital IRCCS San Raggaele Milan) Prof Florian Roghmann (Clinic for Urology, Marien Hospital Herne) Prof Dr Chris Bangma (Anser/ERASMUS University Medical Center Rotterdam) Prof Dr Alain Ruffion (Clinic for Urology, Hospital Civils Lyon) Prof Dr Steven Joniau (Department of Urology, University Hospital Leuven) Prof Dr Karolien Goffien (Department of Nuclear Medicine, University Hospital Leuven) Prof Dr Christian Stief (Department of Urology, University Hospital of the Ludwig Maximilian University of Munich) Prof Dr Steffen Rausch (Department of Urology, University Hospital Tübingen) Prof Andrers Bjartell (Department of Urology, Lund University Hospital)
  6. Who anonymises the data? Dr Isabelle Bußhoff, assistant doctor (Clinic for Urology) Prof Dr Georg Thalmann (Department of Urology, Inselspital Bern) Prof Dr Shahrokh Shariat (Department of Urology, University Hospital Vienna) Prof Roghmann Florian (Department of Urology, Marien Hospital Herne) Prof Dr Francesco Montorsi (Department of Urology, Hospital IRCCS San Raggaele Milan) Prof Dr Chris Bangma (Anser/ERASMUS University Medical Center Rotterdam) Prof Dr Alain Ruffion (Clinic for Urology, Hospital Civils Lyon) Prof Dr Steven Joniau (Department of Urology, University Hospital Leuven) Prof Dr Karolien Goffien (Department of Nuclear Medicine, University Hospital Leuven) Prof Dr Christian Stief (Department of Urology, University Hospital Ludwigs- Maximilian University Munich) Prof Dr Steffen Rausch (Department of Urology, University Hospital Tübingen) Prof Andrers Bjartell (Department of Urology, Lund University Hospital)
  7. Who analyses the data? Dr Isabelle, Bußhoff, Assistant Physician (Clinic for Urology) Prof Dr Jan Philipp Radtke Prof Dr Frederik L. Giesel Prof Dr Lars Schimmöller
  8. Who has access to the assignment key? There is no allocation key as the data is anonymised
  9. Where is the allocation key kept? There is no allocation key as the data is anonymised
  10. How is the assignment key saved? There is no allocation key as the data is anonymised
  11. Where is the research data stored? Please note that the allocation key must not be kept/saved in the same folder/directory as the pseudonymised research data. The data is stored in a password-protected Excel database on the server system of the University Hospital Düsseldorf.

The data from all centres is stored in the PIONEER data platform via the CASTOR Programme of the European Association of Urology (EAU) (https://prostatepioneer.

eu/big-data-platform/pioneer-data-processing/). In the meantime, the applicants have successfully acquired the data storage in PIONEER and the funding for this from the EAU and the EAU Research Foundation.

The data exchange models and data encryption of the PIONEER platform are described below: PIONEER works with two data access models - a centralised and a federated model. In the centralised data exchange model, a copy of the e-identified data is transferred to PIONEER, converted and stored in a central data warehouse for research purposes.

In the federated model, data owners standardise their own data sets and set up analysis tools within their own data environment and make them available on request.

The centralised model will incorporate data by converting population-based registries and epidemiological research data into a common OMOP (Observational Medical Outcomes Partnership) data model to enable the systematic analysis of different observational databases.

Finally, the PIONEER Big Data Platform will not only provide access to data but also analytical tools (ATLAS, R) in a single innovative data platform that utilises two existing data platforms, tranSMART and OHDSI, developed in previous IMI projects. Within PIONEER, the data will not be personally identifiable, i.e. the data has been deidentified to ensure sufficient anonymity so that the person cannot be identified. As a result of this anonymisation process, the data within PIONEER's Big Data platform is not classified as personal data and as such the use of the data complies with all applicable data protection laws at EU level and does not fall within the scope of the General Data Protection Regulation (GDPR) without compromising the clinical relevance of the data. PIONEER achieves this by using two database models: A federated and a centralised database model. In the federated database model, the data does not leave its original location but is queried remotely, with PIONEER bringing the analysis to the data. This essentially means that the data remains anonymous to the researchers accessing the federated database. Data from a variety of sources are effectively 'linked' temporarily to answer specific queries. Individual data providers retain ownership and control of their data and only allow queries in response to authorised requests. This model has been used successfully by other IMI projects such as EMIF-AD.

In the centralised database model, data is physically moved from the data provider to the centralised PIONEER server. To achieve this, PIONEER uses two anonymisation methods. The first is the complete removal of all direct identifiers (such as patient, name, number, photos or other images that could allow identification). The second is "generalisation", which addresses quasi-identifiers. "Generalisation" replaces the values of a particular attribute with less specific values or dilutes the attributes of affected individuals by modifying the respective scales or magnitudes. If the value is a categorical value, it can be changed to another categorical value that denotes a broader concept of the original categorical value. If the value is numeric, it can be changed to a range of values. For example, the granularity of individual birth rates can be reduced by generalising them to a date range or grouping them by month or year.

Other numeric attributes (e.g. age, salary, weight, height or the dose of a drug) can be generalised by banding.

By using the federated database model and applying the de facto anonymisation process to data entered into the centralised database, PIONEER does not process any personal data and therefore complies with data protection law and does not require any special authorisations, consents or approvals in relation to the project (https://prostate-pioneer.eu/big-data-platform/pioneer-data-processing/).

10. Use of image and sound material

a. Will image or sound material be analysed retrospectively as part of this study? Yes b. If "Yes": How is anonymisation carried out here? The data required for the study from the image material used is extracted directly from the image material from the PACS in anonymised form. The image material is therefore limited to the MRI and PET-CT images. Anonymisation is performed automatically within the respective PACS software used at the centre.

11. Utilisation of genetic information

a. Does the study use genetic information that allows the identification of a person? No b. If "Yes": Have the subjects/patients consented to the use of their genetic data for research purposes? Not applicable.

12. Fees

a. How is the study financed? The fees are financed by the EAU Research Foundation: EAU Research Foundation, Mr E.N. van Kleffensstraat 5, 6842 CV Arnhem, The Netherlands. Data storage in PIONEER is funded by the company Exini: EXINI Diagnostics AB, Scheelevägen 27, 223 70 Lund, Sweden.

13. Other information on the study No further details

03

Conditions studied

  • Intermediate-risk Prostate Cancer
  • High-risk Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • PSMA-PET/CT
  • Radical Prostatectomy
  • Intermediate-risk Prostate Cancer
  • High-risk Prostate Cancer
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men at intermediate risk (PSA > 10 ng/ml to 20 ng/ml or Gleason score 7 or cT category 2b) or high risk (PSA > 20 ng/ml or Gleason score ≥ 8 or cT category 2c) who underwent PSMA-PET/CT and mpMRI and subsequentially RP will be analyzed in three different subgroups, assigned to the modalities they underwent in staging in addition to MRI: i) PSMA-PET/CT using 18-F-DCFPyL (subgroup/arm A), ii) PSMA-PET/CT using Gallium-68 (subgroup/arm B) and PSMA-PET/CT using Fluorine-18 (subgroup/arm C). Validation of the accuracy of intraprostatic lesion detection, local staging and of LN-Staging by MRI or PSMA-PET/CT with different tracers is confirmed after radical prostatectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men aged from 45 to 80 years
  2. Men with intermediate risk or high risk csPCa
  3. Men who underwent RP
  4. Men who underwent multiparametric MRI and PSMA-PET/CT before RP

Exclusion criteria

Exclusion Criteria:

a) Men with known prostate cancer, who did not underwent RP and who did not underwent MRI or PSMA-PET-CT

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients staged with PSMA-PET/CT of several tracers prior to Radical Prostatectomy

    Men at intermediate risk (PSA \> 10 ng/ml to 20 ng/ml or Gleason score 7 or cT category 2b) or high risk (PSA \> 20 ng/ml or Gleason score ≥ 8 or cT category 2c) who underwent PSMA-PET/CT and mpMRI followed by RP will be analysed in three different subgroups corresponding to the modalities i) PSMA-PET/CT with 18-F-DCFPyL (subgroup/arm A), ii) Gallium-68 PSMA-PET/CT (subgroup/arm B) and Fluorine-18 PSMA-PET/CT (subgroup/arm C)

    Diagnostic Test: PSMA-11

Interventions

  • Diagnostic testPSMA-11

    PSMA-PET/CT using 68Gallium or 18Fluor or 18DCFPyl as staging prior to Radical Prostatectomy

06

What researchers measure

Primary outcomes

  1. The primary outcome includes the correct LN-staging after radical prostatectomy with the use of PSMA-PET-CT with different tracers and mpMRI in patients with significant prostate cancer (ISUP grade group ≥ 2) of intermediate- or high-risk group

    The primary outcome includes the correct LN-staging after radical prostatectomy with the use of PSMA-PET-CT with different tracers and mpMRI in patients with significant prostate cancer (ISUP grade group ≥ 2) of intermediate- or high-risk group

    Time frame: 01.01.2026-31.12.2026

Secondary outcomes

  1. • ISUP GG prediction by SUV (standardized uptake value) and ADC (apparent diffusion coefficient) values on mpMRI

    • ISUP GG prediction by SUV (standardized uptake value) and ADC (apparent diffusion coefficient) values on mpMRI

    Time frame: 01.12.2026-31.12.2026

  2. Extraprostatic disease

    Extraprostatic disease measured by PSMA-PET/CT and MRI

    Time frame: 01.12.2026-31.12.2026

  3. Significant prostate cancer detection by one modality

    Significant prostate cancer detected by PSMA-PET/CT or MRI that has not been detected by the other modality

    Time frame: 01.12.2026-31.12.2026

07

Study locations

10 sites
08

References and documents

Publications

  • Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. PubMed 27363387 ↗
  • Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14. PubMed 30773328 ↗
  • Mazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F, Stabile A, Moon D, Eapen R, Lawrentschuk N, Montorsi F, Siva S, Hofman MS, Chiti A, Murphy DG, Briganti A, Perera ML. A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. Eur Urol. 2025 Jun;87(6):654-671. doi: 10.1016/j.eururo.2025.03.003. Epub 2025 Mar 27. PubMed 40155242 ↗
  • Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J Nucl Med. 2017 Dec;58(12):1943-1948. doi: 10.2967/jnumed.117.190314. Epub 2017 Jun 15. PubMed 28619734 ↗
  • Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA. Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. J Nucl Med. 2020 Jan;61(1):58-61. doi: 10.2967/jnumed.119.226514. Epub 2019 Jun 14. PubMed 31201249 ↗
  • Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schafer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26. PubMed 27889802 ↗
  • Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. doi: 10.2967/jnumed.115.170720. PubMed 27694178 ↗
  • Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95. doi: 10.1007/s00259-012-2298-2. Epub 2012 Nov 24. PubMed 23179945 ↗
  • Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6. doi: 10.1007/s00259-012-2069-0. Epub 2012 Feb 4. No abstract available. PubMed 22310854 ↗

Individual participant data

Plan to share: No — IPD will not be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Mar 6, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07455097
Collaborators
Marienhospital Herne, San Raffaele University Hospital, Italy, Lund University Hospital, KU Leuven, Fortis Hospital, India, University of Bern, Erasmus Medical Center, Universität Tübingen, Medical University of Vienna, European Association of Urology Research Foundation, University Hospital, Paris, Ludwig-Maximilians - University of Munich
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 6, 2026

Study contacts

Jan Philipp Radtke, Professor Dr. med.
study chair · Heinrich-Heine University, Duesseldorf
Isabelle Busshoff, Dr. med.
principal investigator · Heinrich-Heine University, Duesseldorf
Peter Albers, Professor Dr. med.
study director · Heinrich-Heine University, Duesseldorf

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion